ClinicalTrials.gg
CompletedNCT04126707Updated Sep 8, 2021

The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans

A Phase 1 interventional study of [14C] HQP1351 in Chronic Myeloid Leukemia (CML), sponsored by Ascentage Pharma Group Inc.. Completed at 1 site in China. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-08.

Sponsored by Ascentage Pharma Group Inc. (part of Ascentage Pharma Group International) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in China — 11 open to participants now, 14 under way, 2 of them phase 3. Leukemia, Myelogenous, Chronic, BCR-ABL Positive · China.

Enrollment
36th of 37
6 · median 144
Started
2019
with 2 others
Phase 1
9 of 49
1 open now
Registered
24th of 49
by date
Lead sponsor
2 of 49
Ascentage Pharma Group Inc.

Among the 49 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in China, this one is the 36th largest by enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2019, is one of 9 in phase 1, and was the 24th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

11 of the 49 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 50 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in China, or all of them as a file.
02

Study summary

The objective of this study is to determine the mass balance and routes of excretion of total radioactivity after a single oral 30mg (100µCi) dose of [14C] HQP1351 given as a suspension. For further clinical development, human mass balance data are required to elucidate the absorption, metabolism, and excretion of HQP1351.

03

Conditions studied

  • Chronic Myeloid Leukemia (CML)

Keywords

  • Chronic Myeloid Leukemia
  • HQP1351
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A subject will be eligible for study participation if he meets the following criteria:

  1. Healthy male volunteers between the ages of 18 to 50 years old, inclusive;
  2. Body weight >=50 kg, (body weight(kg)/hight2(m2)) between 19 and 26 kg/m2 (inclusive);
  3. Normal physical findings, clinical laboratory values, vital signs and 12-lead , or any abnormality that is non-;
  4. Male subjects of with partners will be instructed to, and must be willing to practice a highly effective method of for the duration of the study and continuing 1 year after discontinuing treatment with the product.
  5. Must understand, and voluntarily sign the , comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

A subject will not be eligible for study participation if he meets any of the exclusion criteria:

  1. History of or current cardio, pulmonary, endocrine, metabolism, renal, hepatic, gastrointestinal, dermatology, infection, hematology, neurological, mental disease or disorder;
  2. Positive test for , HBeAg, anti-, anti- or syphilis antibody;
  3. Abnormality in blood pressure, including hypertensive BP (SBP>=140 mmHg, or DBP >=90 mmHg), or hypotensive BP (SBP\<90 mmHg, or DBP \<=55 mmHg), Pulse rate\<55 bpm or >100 bpm;
  4. Long- syndrome or family history of it, or QTcB interval > 450 ms; intraventricular blocks or left/right bundle branch block or QRS>120ms; frequent ventricular ectopic beats (any 10s ventricular premature beat >= 1 in screening period); or abnormal resting heart rate (> 100 bpm)
  5. The following abnormal clinical laboratory values

    1. HGB \< LLN or HGB>, and is judged as clinically significant by the investigator;
    2. Abnormal ALB, TP, CRE, , AST, BIL, BUN, GLU value, and is judged as clinically significant by the investigator;
  6. Received any drug within 14 days before taking the drug, including any prescription drug, OTC drug, herbal drug or health care product with medicinal effect;
  7. Received any other investigating products or participated in any clinical trails three month before screening or within 10 t1/2 after receiving other investigating products;
  8. History of or current swallowing disorder, active gastrointestinal diseases, or other diseases that significantly affect absorption, distribution, metabolism and excretion of drugs;
  9. Chronic constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease or history of gastrointestinal surgery and cholecystectomy;
  10. Hemorrhoids or perianal disease with regular/perianal bleeding;
  11. Allergies, have allergies to two or more drugs or foods; or have known allergies to the components of the drug (microcrystalline cellulose, stearic acid, croscarmellose sodium);
  12. Have donated 400ml or more of blood or plasma 3 months prior to the study drug administration, or more than 50ml within 2 weeks prior to administration;
  13. Vaccination was administered within 6 months prior to screening or during screening;
  14. History of drug or alcohol abuse;
  15. Smoking (> 10 cigarette / day), drinking (> 15 g, pure alcohol / day, equivalent to 450 ml beer, 150 ml wine or 50 ml low-alcohol liquor), or abusing drugs within last 3 months;
  16. Subject with mentally ill and could not understand the property, scope and possible consequences of the study;
  17. subject in prison or whose freedom is restricted by administrative or legal issues;
  18. Failure to comply with clinical study protocols, such as non-cooperation, follow-up visit and completion of entire study;
  19. Abnormal coagulation function or known severe bleeding tendency;
  20. Subjects who have participated in radiolabeled clinical study prior to drug administration;
  21. Significant radiation exposure within one year prior to drug administration (more than one exposure from chest X-ray, CT scan, or barium meal examination and radiation-related occupations).
  22. Investigators think that subjects are not suitable to participate in the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    [14C] HQP1351

    To investigate the absorption properties, as well as to evaluate the mass balance and elucidate the pathways of biotransformation after a single oral dose (30mg, 100µCi) of \[14C\] HQP1351 to healthy Chinese male subjects.

    Drug: [14C] HQP1351

Interventions

06

What researchers measure

Primary outcomes

  1. Radioactivity concentration of each blood and plasma sample

    Use liquid scintillation counter to evaluate Radioactivity concentration of each blood and plasma sample

    Time frame: Day 1- Day 15

  2. Radioactivity concentration of each urine samples

    Use liquid scintillation counter to evaluate Radioactivity concentration of each urine sample

    Time frame: Day 1- Day 15

  3. Radioactivity concentration of each feces samples

    Use liquid scintillation counter to evaluate Radioactivity concentration of each feces sample

    Time frame: Day 1- Day 15

  4. Total recovery of radioactivity in urine and feces

    Calculate the total radioactivity in urine and feces based on the radioactivity concentration of each sample

    Time frame: Day 1- Day 15

Secondary outcomes

  1. Plasma drug concentrations

    To determine the plasma concentrations of HQP1351 with validated LC-MS/MS method for obtaining its pharmacokinetics parameters

    Time frame: Day 1- Day 15

  2. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    According to CTCAE v5.0, the number and frequency of adverse events after a single dose of test drug were assessed.

    Time frame: Day 1- Day 15

07

Study locations

1 site
  • The First Affiliated Hospital with Nanjing Medical University
    Nanjing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Jan 2020, 1 month.

Of 56 phase 1 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 95. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2019
First posted
Oct 15, 2019
StartActual
Nov 19, 2019
Primary completionActual
Jan 13, 2020
CompletionActual
Jan 13, 2020
Last update
Sep 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04126707
Collaborators
HealthQuest Pharma Inc.
Responsible party
Sponsor
First posted
Oct 15, 2019
Start date
Nov 19, 2019
Primary completion
Jan 13, 2020
Completion
Jan 13, 2020
Last update
Sep 8, 2021

Study contacts

Feng Shao, Doctor
principal investigator · The First Affiliated Hospital with Nanjing Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olverembatinib

Start the discussion